PAFRK29 Polypeptide Cell Penetration for Anti-Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cardiac fibrosis, particularly those caused by ischemic heart disease, are lacking, and there is a need for more drugs targeting the TGFβ pathway to effectively inhibit fibrosis.
Innovation Solution
A polypeptide named PAFRK29 with improved cell penetrability is developed, which can efficiently enter target cells, inhibit the Smad2/3 signaling pathway, and reduce the expression of fibrosis markers and extracellular matrix proteins, thereby inhibiting fibrosis in target organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptide drugs are used to inhibit fibrosis, then selectivity and effectiveness are improved, but cell penetrability deteriorates
Solution Approach 1:
The patent modifies the physical and chemical parameters of the polypeptide by introducing a cell-penetrating peptide sequence (CPP) at the N-terminus. This sequence contains specific amino acid compositions (rich in basic residues like arginine and lysine) that change the overall charge and structural properties of the polypeptide, enabling it to penetrate cell membranes while maintaining its fibrosis-inhibiting function.
Solution Approach 2:
The invention creates a composite polypeptide structure by combining two functional domains: a cell-penetrating peptide sequence (CPP) and a fibrosis-inhibiting polypeptide sequence. The CPP acts as a delivery vehicle that facilitates cellular uptake, while the downstream sequence provides the therapeutic anti-fibrotic activity, achieving both penetrability and selectivity.
2Reliability
If polypeptide drugs are used to inhibit fibrosis, then effectiveness is improved, but ease of operation deteriorates
Solution Approach 1:
The patent changes the pharmacokinetic parameters of the polypeptide by adding the cell-penetrating sequence, which enhances cellular internalization efficiency. This modification allows the drug to be administered systemically and still reach intracellular targets effectively, improving ease of administration compared to non-penetrating polypeptides that would require direct local delivery.
3Reliability
If polypeptide drugs are used to target TGFβ pathway, then anti-fibrosis efficacy is improved, but molecular size increases
Solution Approach 1:
The patent segments the therapeutic function into two parts: a small cell-penetrating peptide sequence (typically 5-20 amino acids) and a larger fibrosis-inhibiting sequence. The CPP segment performs the delivery function, while the downstream segment targets the TGFβ pathway, allowing the overall molecule to be more manageable in size compared to traditional large protein drugs while maintaining efficacy.
Data Source
AI summary
The present invention relates to a polypeptide and application thereof in preparation of an anti-fibrosis drug. The polypeptide of the present invention has an amino acid sequence as shown in SEQ ID NO. 1. The polypeptide of the present invention has good cell penetrability, can efficiently enter target cells, can permanently exist in a target organ after reaching the target organ, and has no obvious toxic or side effect in an effective dose range; can effectively inhibit a classic signaling pathway of fibrosis, thereby inhibiting expression of proteins, such as fibrosis markers and extracellular matrices; and can effectively inhibit fibrosis of a target organ and improve functions of the target organ. A new drug and a solution are provided for clinical treatment of fibrosis diseases, and the polypeptide has important significance for improving a clinical treatment effect of the fibrosis diseases and improving life quality of patients.